Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Candidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancer.

Banno K, Nogami Y, Kisu I, Yanokura M, Umene K, Masuda K, Kobayashi Y, Yamagami W, Susumu N, Aoki D.

Int J Mol Sci. 2013 Jun 6;14(6):12123-37. doi: 10.3390/ijms140612123. Review.

2.

Epigenetic mechanisms in endometrial cancer.

Stampoliou A, Arapantoni-Dadioti P, Pavlakis K.

J BUON. 2016 Mar-Apr;21(2):301-6. Review.

PMID:
27273937
3.

Epigenetic changes as prognostic predictors in endometrial carcinomas.

Farkas SA, Sorbe BG, Nilsson TK.

Epigenetics. 2017 Jan 2;12(1):19-26. doi: 10.1080/15592294.2016.1252891. Epub 2016 Nov 22.

4.

MicroRNAs in endometrial cancer.

Banno K, Yanokura M, Kisu I, Yamagami W, Susumu N, Aoki D.

Int J Clin Oncol. 2013 Apr;18(2):186-92. doi: 10.1007/s10147-013-0526-9. Epub 2013 Feb 5. Review.

PMID:
23380959
5.

Carcinogenic mechanisms of endometrial cancer: involvement of genetics and epigenetics.

Banno K, Yanokura M, Iida M, Masuda K, Aoki D.

J Obstet Gynaecol Res. 2014 Aug;40(8):1957-67. doi: 10.1111/jog.12442. Review.

PMID:
25131761
6.

[The role of miRNA in endometrial cancer in the context of miRNA 205].

Wilczyński M, Danielska J, Dzieniecka M, Malinowski A.

Ginekol Pol. 2015 Nov;86(11):856-61. Review. Polish.

PMID:
26817318
7.

Epigenetic inactivation of EFEMP1 is associated with tumor suppressive function in endometrial carcinoma.

Yang T, Qiu H, Bao W, Li B, Lu C, Du G, Luo X, Wang L, Wan X.

PLoS One. 2013 Jun 28;8(6):e67458. doi: 10.1371/journal.pone.0067458. Print 2013.

8.

The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.

Hsiao SM, Chen MW, Chen CA, Chien MH, Hua KT, Hsiao M, Kuo ML, Wei LH.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1556-65. doi: 10.1245/s10434-015-4379-5. Epub 2015 Jan 23.

PMID:
25613390
9.

ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma.

Romero-Pérez L, López-García MÁ, Díaz-Martín J, Biscuola M, Castilla MÁ, Tafe LJ, Garg K, Oliva E, Matias-Guiu X, Soslow RA, Palacios J.

Mod Pathol. 2013 Nov;26(11):1514-24. doi: 10.1038/modpathol.2013.93. Epub 2013 Jun 7.

10.

Discovery and validation of methylation markers for endometrial cancer.

Wentzensen N, Bakkum-Gamez JN, Killian JK, Sampson J, Guido R, Glass A, Adams L, Luhn P, Brinton LA, Rush B, d'Ambrosio L, Gunja M, Yang HP, Garcia-Closas M, Lacey JV Jr, Lissowska J, Podratz K, Meltzer P, Shridhar V, Sherman ME.

Int J Cancer. 2014 Oct 15;135(8):1860-8. doi: 10.1002/ijc.28843. Epub 2014 Mar 31.

11.

Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review).

Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N, Aoki D.

Oncol Rep. 2009 Nov;22(5):967-72. Review.

PMID:
19787208
12.

Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.

Fiolka R, Zubor P, Janusicova V, Visnovsky J, Mendelova A, Kajo K, Lasabova Z, Plank L, Danko J.

Oncol Rep. 2013 Dec;30(6):2878-86. doi: 10.3892/or.2013.2752. Epub 2013 Sep 25.

PMID:
24068440
13.

Methylation of tumor suppressor gene CDH13 and SHP1 promoters and their epigenetic regulation by the UHRF1/PRMT5 complex in endometrial carcinoma.

Sheng Y, Wang H, Liu D, Zhang C, Deng Y, Yang F, Zhang T, Zhang C.

Gynecol Oncol. 2016 Jan;140(1):145-51. doi: 10.1016/j.ygyno.2015.11.017. Epub 2015 Nov 18.

PMID:
26597461
14.

The role of microRNAs in the pathogenesis of endometrial cancer: a systematic review.

Sianou A, Galyfos G, Moragianni D, Andromidas P, Kaparos G, Baka S, Kouskouni E.

Arch Gynecol Obstet. 2015 Aug;292(2):271-82. doi: 10.1007/s00404-015-3660-y. Epub 2015 Feb 20. Review.

PMID:
25697925
15.

Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment.

Zhou XC, Dowdy SC, Podratz KC, Jiang SW.

Gynecol Oncol. 2007 Oct;107(1):143-53. Epub 2007 Aug 13. Review.

PMID:
17692907
16.

MicroRNA: The Potential Regulator of Endometrial Carcinogenesis.

Kontomanolis EN, Koukourakis MI.

Microrna. 2015;4(1):18-25. Review.

PMID:
26088599
17.

The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905.

Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J.

PLoS One. 2014 Apr 14;9(4):e94167. doi: 10.1371/journal.pone.0094167. eCollection 2014.

18.

Current concepts in the pathology and epigenetics of endometrial carcinoma.

Arafa M, Somja J, Dehan P, Kridelka F, Goffin F, Boniver J, Delvenne P.

Pathology. 2010 Dec;42(7):613-7. doi: 10.3109/00313025.2010.520307. Review.

PMID:
21080868
19.

Comprehensive miRNA profiling of surgically staged endometrial cancer.

Cohn DE, Fabbri M, Valeri N, Alder H, Ivanov I, Liu CG, Croce CM, Resnick KE.

Am J Obstet Gynecol. 2010 Jun;202(6):656.e1-8. doi: 10.1016/j.ajog.2010.02.051. Epub 2010 Apr 18.

20.

Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia.

Zauber P, Denehy TR, Taylor RR, Ongcapin EH, Marotta S, Sabbath-Solitare M.

Int J Gynecol Cancer. 2015 Jun;25(5):863-8. doi: 10.1097/IGC.0000000000000421.

PMID:
25768080

Supplemental Content

Support Center